Welcome to our dedicated page for Eargo news (Ticker: EAR), a resource for investors and traders seeking the latest updates and insights on Eargo stock.
Eargo, Inc. (Nasdaq: EAR) delivers innovative hearing solutions through discreet, FDA-regulated devices designed for modern lifestyles. This page aggregates official announcements and market-moving developments for investors tracking this medical technology pioneer.
Access real-time updates on Eargo's retail expansions, insurance partnerships, and product innovations like the self-fitting Eargo 7. Monitor financial performance updates and leadership changes affecting corporate strategy. Our curated news feed simplifies tracking key milestones in hearing aid accessibility and omni-channel growth.
Key coverage includes earnings reports, FDA clearances, retail availability expansions through partners like Best Buy, and insurance coverage progress. Bookmark this page for verified updates on Eargo's cost management initiatives and consumer-focused technological advancements in hearing health.
Eargo, a medical device company focused on improving hearing loss solutions, will announce its Q1 2021 financial results on May 12, 2021, after market close. A conference call will follow at 2:00 p.m. PT to discuss these results. Eargo offers virtually invisible, rechargeable hearing aids that are FDA regulated and cost approximately half of traditional hearing aids. Their latest product, the Eargo Neo HiFi, launched in January 2020, provides enhanced audio capabilities. More details are available on Eargo's website.
Eargo, Inc. (Nasdaq: EAR) has released a survey highlighting the impact of the pandemic on hearing health ahead of World Hearing Day on March 3. The survey, involving 2,000 Americans aged 40 and older, indicates that while many are optimistic about returning to normalcy, 28% suspect they have hearing loss without testing. Notably, 61% express a heightened awareness of health, but hearing remains overlooked. The findings emphasize the need for increased access to hearing tests and the potential of telehealth, used by 41% of respondents during the pandemic.
Eargo, Inc. (Nasdaq: EAR) reported impressive financial results for Q4 and full year 2020, showing significant growth. Q4 net revenues reached $22.4 million, a 110.8% increase year-over-year, while full year revenues totaled $69.2 million, also up 110.9% from 2019. Gross margin climbed to 70.6% in Q4 and 68.4% for the year. Eargo forecasts 2021 revenue between $87 million and $93 million. The company also highlighted improved operational efficiency, with S&M expenses as a percentage of revenues decreasing significantly.
Eargo, Inc. (Nasdaq: EAR), a medical device company focused on enhancing the quality of life for individuals with hearing loss, announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference. CEO Christian Gormsen will present via webcast on February 26, 2021, at 12:00 PM Eastern Time. The presentation will be accessible on Eargo's website and available for replay for 90 days. Eargo’s innovative hearing aids are FDA registered and address key challenges of traditional devices, offering a consumer-friendly, cost-effective alternative.
Eargo, Inc. (Nasdaq: EAR) announced its plans to release financial results for Q4 and full year 2020 on February 25, 2021, after market close. A conference call will follow at 1:30 p.m. PT to discuss these results. Eargo is focused on enhancing quality of life for individuals with hearing loss through innovative, accessible, and cost-effective hearing aids. Their latest product, the Eargo Neo HiFi, launched in January, boasts improved audio capabilities and is positioned at half the cost compared to traditional hearing aids.
Ally Lending has partnered with Eargo to enhance financing options for consumers needing hearing aids. This collaboration aims to eliminate cost barriers, allowing more individuals access to Eargo's innovative hearing devices. Ally Lending reported a significant 75% year-over-year growth in loan origination for 2020. The partnership is positioned to address the financial challenges faced by Americans, particularly amid the pandemic, by offering easy online applications and low monthly payments. Eargo's hearing aids are designed to be virtually invisible and affordable, addressing major adoption challenges in the market.
Eargo, Inc. (Nasdaq: EAR) reported its preliminary unaudited net revenue for Q4 and full year 2020, showing significant growth. For Q4 2020, net revenue is projected at $22.2 million, up 109% year-over-year, with 12,050 systems shipped, a 67% increase. Full year 2020 net revenue is expected to be $69 million, marking a 110% growth, with 38,200 systems shipped, up 68%. Eargo will present at the J.P. Morgan Healthcare Conference on January 12, 2021, discussing strategic initiatives and growth opportunities.
Eargo, a medical device company focused on enhancing life for those with hearing loss, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 2:00 PM ET. Christian Gormsen, Eargo’s CEO, will lead the presentation. The live web cast and slides are accessible at Eargo's website and will remain available for replay until February 12, 2021. Eargo offers innovative, virtually invisible hearing aids that are significantly less expensive than traditional options, enabling broader access and adoption.
Eargo reported strong performance for Q3 2020, with net revenues of $18.2 million, a 135.3% increase year-over-year. The company shipped 10,077 systems, up 91.7%, achieving a gross margin of 70.1%, a 16.5 percentage point improvement. Loss from operations narrowed to ($7.6) million compared to ($12.0) million in Q3 2019. The company completed its IPO on October 20, 2020, raising approximately $148 million. Eargo expects full year 2020 revenues of $64.5 million, indicating a projected 97% growth.
